|
Aug 14
|
Adherex Technologies Inc. (FENC) Reports Q2 Loss, Beats Revenue Estimates
|
|
Aug 14
|
Fennec Pharmaceuticals Q2 Net Loss Narrows as Revenue Advances
|
|
Aug 14
|
Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update
|
|
Aug 13
|
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 12
|
Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 11
|
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates
|
|
Aug 11
|
Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025
|
|
Jul 31
|
Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?
|
|
Jul 15
|
Recent Price Trend in Adherex Technologies (FENC) is Your Friend, Here's Why
|
|
Mar 11
|
Fennec Pharmaceuticals Inc (FENC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
|
Mar 11
|
Q4 2024 Fennec Pharmaceuticals Inc Earnings Call
|
|
Mar 10
|
Wedbush Reviews Fennec Pharmaceuticals' Q4
|
|
Mar 10
|
Investing in Fennec Pharmaceuticals (NASDAQ:FENC) five years ago would have delivered you a 38% gain
|
|
Mar 10
|
Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
|
|
Oct 1
|
The past three years for Fennec Pharmaceuticals (NASDAQ:FENC) investors has not been profitable
|
|
Sep 5
|
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
|
|
Aug 15
|
Fennec Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations
|
|
Aug 14
|
Q2 2024 Fennec Pharmaceuticals Inc Earnings Call
|
|
Aug 13
|
Fennec Q2 Loss Stays Constant as Revenue More Than Doubles, Appoints Jeffrey Hackman as CEO
|
|
Aug 13
|
Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
|